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ABSTRACT. Objective: Serotonergic system contributes to
the regulation of hypothalamus-pituitary-adrenal axis. In hu-
mans, serotonergic agonists increase PRL, ACTH, and cortisol,
while serotonin (5HT) influence on GH is controversial. Cen-
tral 5HT activity and neuroendocrine function change during
lifespan. Design: To clarify the neuroendocrine response to
5HT across lifespan, we assessed ACTH, cortisol, DHEA, PRL,
and GH responses to citalopram (CT) in young adults (YA)
(no.=12, 29.2±1.7 yr mean±SEM), middle aged (MA) (no.=12,
54.3±0.9 yr), and elderly (ES) (no.=12, 69.3±0.9 yr) males.
All the subjects received placebo (saline iv over 120 min) or
CT (20 mg iv over 120 min). Blood samples were taken every
15 min up to 240 min. Results: During placebo, ACTH, corti-
sol, GH, and PRL were similar in all groups while DHEA
showed an age-dependent reduction from middle age
(p<0.001). During CT, ACTH, and cortisol were higher than
during placebo in YA (p<0.05) and even more in MA (p<0.01
vs placebo, p<0.05 vs YA); in ES, the increase of both ACTH
and cortisol (p<0.05 vs placebo) was lower than in MA
(p<0.05) and higher than in YA (p<0.05 for cortisol only). No
changes were observed for DHEA, GH, and PRL in any group.
Conclusions: Corticotrope response to CT is age-dependent
in normal men, being amplified starting from middle age,
suggesting precocious changes in the serotonergic neu-
roendocrine control during lifespan. CT is a useful tool to
evaluate the age-dependent serotonergic function in humans.
(J. Endocrinol. Invest. 33: 657-662, 2010)
©2010, Editrice Kurtis
INTRODUCTION
Serotonergic system is known to play a central role in the
regulation of neurondocrine activity in animals and hu-
mans (1, 2). There is evidence that it is involved in the
mediation of the hippocampal feedback regulation of the
hypothalamus-pituitary-adrenal (HPA) axis. In fact, in vit-
ro studies showed that serotonin (5HT) increases hip-
pocampal mRNA expression of glucocorticoid receptors,
in culture cells of rats, mice, and guinea pigs especially
during certain periods of fetal life (3-5). In the hypotha-
lamic paraventricular nucleus, direct synaptic connections
between serotonergic neurons and CRH-secreting neu-
rons have also been demonstrated (6) and, at this level,
5HT exerts an excitatory effect on the CRH secretion, with
a resulting increase in ACTH and cortisol circulating lev-
els (7). The activation of both 5HT2c (8) and 5HT1A/5HT2A
receptors seems to mediate these neuroendocrine ef-
fects of 5HT (9-11).
In humans, serotonergic agonists have been shown to in-
crease PRL, ACTH, and cortisol levels after acute admin-
istration (12-14) while the role of 5HT on GH secretion in
physiological conditions is less clear (12, 13).
Based on this evidence, neuroendocrine challenge tests
with serotonergic agonists have been often used to in-
vestigate the activity of the serotonergic system in both
physiological and pathological conditions. The latter in-
clude psychiatric disorders, such as major depression and
eating disorders, in which an impairment of serotonergic
system as well as a central HPA hyperactivity have been
demonstrated by most of the Authors (12, 13).
Besides psychiatric disorders, another condition charac-
terized by serotonergic impairment and HPA alterations
is aging, in which a decrease in 5HT concentrations has
been demonstrated (15, 16). Many studies have also em-
phasized the existence of receptor loss in this period of
life, as pointed out by both post mortem and in vivo anal-
yses (17, 18) by using 5HT ligands and neuroimaging (19-
21). The extent of 5HT receptor loss is reported to be 10-
17% “per decade” starting from the levels at 20 yr of age
(20-22). The most involved receptor subtypes are 5HT1A
and 5HT2A, while no clear reduced affinity of the re-
maining receptors has been described (20-23). Indeed,
Sheline and co-workers (21) have shown that the age-re-
lated serotonergic receptor loss (especially for 5HT2A) is
greatest in middle age, then levelling off after the 5th
decade, in widely scattered brain regions, including the
hippocampus. This suggests that middle age is a crucial
period of life for the change in the neuroendocrine con-
trol of 5HT. A decline in central 5HT activity, expressed as
a reduced PRL response to both 5HT releasing agents
and receptor agonists, has also been shown in elderly
subjects (24-26). Moreover, a recent work indicated a
positive correlation between allelic variants of the 5HT
transporter gene, morning cortisol concentrations, and
cognitive impairment in a population of elderly subjects
(27), thus emphasizing the link between serotonergic ac-
tivity, HPA axis, and brain function in aging.
Since the serotonergic probes used so far have been crit-
icized with respect to their limited specificity for sero-
Key-words: ACTH, citalopram, cortisol, DHEA, lifespan, SSRI.
Correspondence: E. Arvat, MD, Division of Endocrinology and Metabolism, Depart-
ment of Internal Medicine, Ospedale San Giovanni Battista-Molinette, C.so Dogliot-
ti 14, 10126 Turin, Italy.
E-mail: emanuela.arvat@unito.it
Accepted November 30, 2009.
First published online April 22, 2010.
Neuroendocrine effects of citalopram, a selective serotonin
re-uptake inhibitor, during lifespan in humans
R. Berardelli1, E. Margarito2, F. Ghiggia2, A. Picu1, M. Balbo1, L. Bonelli1, R. Giordano3,
I. Karamouzis1, M. Bo2, E. Ghigo1, and E. Arvat1
1Division of Endocrinology and Metabolism, Department of Internal Medicine; 2Department of Medical and Surgical Disciplines,
Sections of Geriatrics; 3Department of Clinical and Biological Science, University of Turin, Turin, Italy













Neuroendocrine effect of citalopram in humans
658
tonergic system (28, 29), or raise safety concerns, as in
the case of fenfluramine (30, 31), some authors have sug-
gested citalopram (CT), a specific 5HT reuptake inhibitor
(SSRI), as a suitable neuroendocrine probe to investigate
the serotonergic function (14, 28-34).
In order to clarify the neuroendocrine effects of 5HT
across lifespan, in the present study we assessed the
responses of ACTH, cortisol, DHEA, PRL, and GH to iv
CT administration in a group of healthy young, middle
aged and elderly volunteers. In fact, while middle age is
probably a crucial period of life for the changes in the
serotonergic activity, the majority of previous studies
evaluated the age-related neurohornomal response to




Twelve male young adults (YA) [age 29.2±1.7 yr mean±SEM,
body mass index (BMI) 22.3 kg/m2], 12 male middle aged (MA)
(54.3±0.9 yr, BMI 23.7 kg/m2) and 12 male elderly (ES)
(69.3±0.9 yr, BMI 24.2 kg/m2) subjects were studied. All the
subjects were screened to exclude acute physical illness or any
acute or prior psychiatric disorder by physical examination,
laboratory testing, and structured interview. None of the sub-
jects had history of alcohol, substance dependence or recent
stress events. They had been free of any drug known to influ-
ence HPA axis and serotonergic system, especially antide-
pressants or neuroleptics, for at least 3 months before the
study. The study protocol had been approved by an indepen-
dent, local Ethics Committee and written, informed consent
was obtained from all subjects.
Study design
All the subjects were randomized to receive placebo (saline iv
over 120 min) or CT (20 mg iv over 120 min) with a 1-week
washout between treatments. CT infusion was slower that in pre-
vious studies, in order to avoid side effects (like nausea, sick-
ness, dizziness, distress, and restlessness) experienced with faster
infusions (10 or 20 mg over 15-30 min) (28, 30, 35, 36).
After an overnight fasting, the tests began in the morning at
08:30-09:00 h, 30 min after an indwelling catheter had been
placed into an antecubital vein of the forearm, that was main-
tained patent until the end of the study by slow infusion of iso-
tonic saline.
Blood samples were taken every 15 min from 0 (starting of place-
bo or CT infusion) to +240 min for all the subjects. ACTH, cor-
tisol, DHEA, PRL, and GH levels were analyzed at each time
point.
Hormone measurements
Plasma ACTH levels (pg/ml) were measured in duplicate by a
immunoradiometric assay (IRMA CTK, DiaSorin, Vercelli, Italy).
The sensitivity of the assay was 1.2 pg/ml. The range of inter-
and intra-assay coefficients of variations were 4.4-16.2% and 1.3-
7.9%, respectively.
Serum cortisol levels (µg/l) were measured in duplicate by a ra-
dioimmunometric assay (RIA, Immunotech, France). The sensi-
tivity of the assay was 3.62 µg/l. The range of inter- and intra-as-
say coefficients of variations were 5.3-9.2% and 2.8-5.8%, re-
spectively.
Serum DHEA levels (µg/l) were measured in duplicate by a ra-
dioimmunometric assay (RIA, Chematil, Webster, Texas, USA).
The sensitivity of the assay was 0.09 µg/l. The range of inter-
and intra-assay coefficients of variations were 10.68-13.72% and
5.2-6.4%, respectively.
Serum GH levels (µg/l) were measured in duplicate by a im-
munoradiometric assay (IRMA CT, Radim, Pomezia, Italy). The sen-
sitivity of the assay was 0.04 µg/l. The range of inter- and intra-
assay coefficients of variations were 4.6% and 3.7%, respectively.
Serum PRL levels (µg/l) were measured in duplicate by a im-
munoradiometric assay (IRMA, Immunotech, France). The sen-
sitivity of the assay was 0.5 µg/l. The range of inter- and intra-as-
say coefficients of variations were 6.2-8.0% and 1.6-2.8%, re-
spectively.
Statistical analysis
Hormonal responses are expressed as mean, SEM, and relative
95% confidence interval (95% CI) of either absolute values or
area under curves (AUC) calculated by trapezoidal integration.
For each subject the differences between placebo and CT were
computed at each time point and analysis of variance for re-
peated measures model (Greenhouse-Geisser estimation) was
used to analyse the variation of the differences among YA, MA,
and ES subjects in the 4 h of hormonal evaluation. Variations
between placebo and CT effects at each time point and differ-
ences between YA, MA, and ES subjects (separately for place-
bo and CT) were compared by means of non-parametric
Wilcoxon and Mann-Whitney test, respectively. Differences with
a p-value <0.05 were considered statistically significant. SPSS
(Statistical Package for the Social Science), version 15.0 was
used for the analysis.
Fig. 1 - ACTH, cortisol, and DHEA levels (mean±SEM) during placebo in young adults (YA), middle aged (MA), and elderly (ES) subjects.
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RESULTS
During placebo session, a trend toward a decrease in the
ACTH and cortisol levels were observed in all groups,
without any significant difference recorded between each
group (Fig. 1). On the contrary, DHEA levels were signif-
icantly higher (p<0.001) in YA compared to MA and ES at
each time point; the two latter groups showed similar
hormonal levels (Fig. 1). There were no statistically sig-
nificant differences among the groups for GH and PRL
levels (Table 1).
Looking at the CT effect, in YA ACTH concentrations
were significantly increased by CT starting from time
point 60 min up to 120 min (p<0.05) compared to the
same time points during placebo session; cortisol secre-
tion reached a significant increase (p<0.05) at 30 min, 45,
and 60 min (Fig. 2). In MA, CT significantly increased
ACTH starting from 15 min up to 165 min (p<0.01) and
cortisol from 30 min up to 195 min (p<0.01) compared
to placebo session (Fig. 2). In ES, ACTH levels were also
significantly higher during CT (p<0.01) than during place-
bo, starting from 45 min up to 135 min, while cortisol lev-
els were increased from 45 min up to 75 min (p<0.05)
(Fig. 2).
No significant differences in GH, PRL, and DHEA secre-
tion were observed between CT and placebo session in
any group, although DHEA levels showed a trend toward
increase during CT, especially in MA group (Table 1).
For CT session, an interaction effect of group has been
recorded. YA vsMA: ACTH levels were significantly high-
er in MA from 30 min up to 90 min (p<0.05), while corti-
sol showed an even higher significant increase in MA,
starting from 15 min to 195 min (p<0.01) (Fig. 3). YA vs
ES: no differences were observed for ACTH, while corti-
sol was significantly higher in ES from 15 min up to 75
min (p<0.05) (Fig. 3). MA vs ES: ACTH levels were high-
er in MA from 15 min to 90 min and at 225 min and 240
min (p<0.01), while cortisol showed a significant higher
increase in MA from time 60 min to time 180 min
(p<0.05) (Fig. 3).
The statistical difference recorded for DHEA levels, which
was higher at every time point in YA with respect to MA
and ES (p<0.001) simply reflected the higher levels in YA
already observed during placebo, as no response to CT
has been shown in any group (Table 1). There were no
statistically significant differences among the groups for
GH and PRL levels (Table 1).
Side effects
CT administration induced a transient local discomfort
(burning sensation at the beginning of the infusion) in 1
YA and 2 ES.
Fig. 2 - ACTH and cortisol levels (mean±SEM) in young adults (YA), middle aged (MA), and elderly (ES) subjects during placebo and
citalopram (CT) infusion.
Table 1 - GH, PRL, and DHEA area under curves (AUC)0-240±SEM
during placebo or citalopram infusion in young adults (YA), mid-
dle aged (MA) and elderly (ES) subjects.
AUC0-240±SEM YA MA ES
Placebo
GH µg/l/h 183.8±111.8 172.6±115.4 142±14.9
PRL µg/l/h 1251.3±195.3 1140.5±88.1 1082.8±8.1
DHEA µg/l/h 2358.2±191.3 838.3±94.4 704.5±62.5
Citalopram
GH µg/l/h 209.1±60.7 194.3±132.3 169.9±17.3
PRL µg/l/h 1299.9±333.5 1184.5±101.2 1123.4±94.4
DHEA µg/l/h 2416.4±158.4 865.8±211.4 749.8±109.3
n
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DISCUSSION
The results of our study demonstrate an age-dependent
stimulatory effect of CT on corticotrope secretion in nor-
mal men. In fact, both ACTH and cortisol levels were sig-
nificantly increased by acute CT infusion in YA, MA, and
ES subjects, but a transient HPA hyper-responsiveness
to CT has been recorded in MA, with hormonal levels
clearly higher than in YA and ES subjects. Our findings
also showed that DHEA secretion is clearly reduced start-
ing from middle age, with no response to SSRI adminis-
tration. Conversely, basal lactotrope and somatotrope
activities were similar in all groups and no response to
CT was observed in any period of adult life.
An age-related hyperactivation of HPA axis has been
shown in both animals and humans, as demonstrated by
the evidence of an increase in both basal and stimulated
ACTH and cortisol concentrations in aging (37-40). How-
ever, some studies failed to observe any significant ef-
fect of age on either ACTH or cortisol levels (41-44) or
even showed a decreased basal cortisol secretion with
advancing age (45, 46). In agreement with these studies,
we did not observe any significant age-related difference
in term of morning basal ACTH and cortisol levels. This is
not surprising, considering that the hyperactivation of
HPA axis in the elderly is mostly occurring not at the peak
level but rather during the nadir of the circadian rhythm,
likely reflecting the age-related reduction in the negative
feedback action of circulating glucocorticoids (37-39).
In humans, a stimulatory effect on both ACTH and corti-
sol secretion has been demonstrated after acute admin-
istration of several serotonergic agonists (12-14, 32). CT
has been shown as a selective SSRI, with no known in-
trinsic activity at 5HT receptors or other receptor fami-
lies (28, 30, 32) and it has been suggested as a suitable
neuroendocrine probe to evaluate the central seroton-
ergic activity (14, 28-34). The SSRI-induced inhibition of
5HT reuptake increases 5HT levels in the synaptic cleft,
thereby prolonging the activation of post-synaptic 5HT
receptors. We have previously demonstrated that acute
serotonergic stimulation by citalopram increases ACTH
and PRL levels in normal young subjects while some al-
terations in the neuroendocrine response to this com-
pound was present in anorexic patients (47).
While a reduction in 5HT function as well as a derange-
ment in the neuroendocrine response to 5HT has been
demonstrated in aging, little information is available
about the period of life in which serotonergic neuroen-
docrine activity starts to change.
Our findings showed that the corticotrope response to SS-
RI clearly changes across lifespan in normal men, starting
Fig. 3 - ACTH and cortisol levels
(mean±SEM) during citalopram (CT) in-
fusion in young adults (YA), middle aged
(MA), and elderly (ES) subjects.
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from middle age. The ACTH and cortisol responses to CT
were, in fact, clearly amplified in MA subjects, whereas on-
ly cortisol response was significantly increased in aged sub-
jects, in comparison with YA. These results seem, appar-
ently, in contrast with the progressive reduction of 5HT
function observed with advancing age and, especially, with
the evidence of a marked 5HT receptors loss in middle
age (20-22). Nevertheless, it may be hypothesized that,
during this period of life, the 5HT receptor loss in the
synaptic cleft leads to an up-regulation of the remaining
receptors, with a resulting temporary hypersensitivity to
serotonergic challenges. On the other hand, the progres-
sive reduction in the HPA response to CT from middle to
advanced age agrees with the hypothesis that the up-reg-
ulation mechanism is turned-off with advancing age, prob-
ably reflecting an age-related sensitivity loss of the re-
maining receptors. Moreover, a reduction of 5HT concen-
trations and/or a decrease in 5HT transporter concentra-
tions, demonstrated in aged brain (15, 16), could also ex-
plain the progressive reduction in the HPA response to CT
from middle to advanced age observed in our study.
Taking into account the evidence of the age-related de-
cline in the brain 5HT activity, the basically similar HPA re-
sponse to CT, in our YA and ES subjects was quite un-
expected and not easy to explain. At a first glance, this
finding could allow to state that advanced age may have
no major impact on SSRI-induced HPA stimulation. How-
ever, the lack of remarkable difference in the hormonal
response between YA and ES, observed in our study,
may be consistent with the reduced responsiveness of
the HPA axis to the negative feedback of the ES, lead-
ing to a relative HPA hyperactivity, which may mask the
age-related decline in the 5HT function.
Moreover, in both YA and ES subjects, but not in MA, the
adrenal response to CT was slightly anticipated or con-
comitant with the corticotrope response to the drug; this
hormonal pattern is not usual for central stimulations which
normally release ACTH before cortisol (48). Although SS-
RI receptors have been identified in both normal and hy-
perplastic adrenal gland, data in humans showed a direct
stimulatory effect of SSRI in bilateral ACTH-independent
bilateral macronodular adrenal hyperplasia only, possibly
reflecting the increased zona fasciculata expression or ab-
normal function of “eutopic” 5-HT4 receptor (48). Howev-
er, a possible age-related sensitivity of normal adrenal
gland to direct SSRI stimulation cannot be ruled out, al-
though our present data could simply reflect the small
number of subjects enrolled in our study.
Interestingly, we also found a precocious decline in DHEA
secretion across lifespan, starting from middle age, where
the hormonal levels were similar to those in aging. This in-
dicates that the reduction in DHEA synthesis and secre-
tion, which has been hypothesized to reflect a selective
age-related atrophy of the reticularis zone (46), starts be-
fore aging. DHEA secretion is usually very sensitive to
the increase in ACTH concentrations, either after admin-
istration of exogenous ACTH or in response to endoge-
nous ACTH release (49-51). In our study, in spite of a sig-
nificant ACTH response to CT in all groups, no DHEA re-
sponse was recorded, although a trend toward increase
was observed in middle age, where ACTH reached the
highest levels. This is likely to reflect the small number
of subjects studied, although a direct action of seroton-
ergic compounds on adrenal gland cannot be ruled out.
Finally, our findings did not show a significant effect of CT
infusion on either PRL or GH secretion across lifespan, in
agreement with controversial data previously reported (12,
13). Concerning PRL secretion, a possible sex-related in-
fluence of SSRI on lactotrope function can be hypothe-
sised. In fact, most previous studies, which demonstrated
a significant PRL response to different 5HT-agonists, re-
ferred to females only, whereas no significant PRL response
to D-fenfluramine was reported in males by some authors
(52, 53). Moreover, two other possible explanations can
be taken into account: first, we performed the test in the
morning, while previous studies performed the test in the
afternoon, to avoid the morning decline in plasma PRL and
cortisol levels (28, 30, 35); second, the rate of CT infusion
was smaller in our than in previous studies, which used
faster infusion rates, up to 20 mg in 15 min (36).
In conclusion, our study demonstrated that corticotrope
response to CT is age-dependent in normal men, being
clearly amplified in middle age with a progressive decline
with advancing age. This suggests precocious changes in
the serotonergic neuroendocrine control during human
lifespan, possibly reflecting age-related changes in 5HT
receptor expression and/or sensitivity. These data also in-
dicate that CT is a useful tool to evaluate the age-de-





1. Andrews MH, Kostaki A, Setiawan E, et al. Developmental regula-
tion of the 5-HT7 serotonin receptor and transcription factor NGFI-
A in the fetal guinea-pig limbic system: influence of GCs. J Physiol
2004, 555: 659-70.
2. Lowry CA. Functional subsets of serotonergic neurones: implications
for control of the hypothalamic-pituitary-adrenal axis. J Neuro-
endocrinol 2002, 14: 911-23.
3. Erdeljan P, MacDonald JF, Matthews SG. Glucocorticoids and sero-
tonin alter glucocorticoid receptor (GR) but not mineralocorticoid
receptor (MR) mRNA levels in fetal mouse hippocampal neurons, in
vitro. Brain Res 2001, 896: 130-6.
4. Meaney MJ, Diorio J, Francis D, et al. Postanatal handling increases
the expression of cAMP-inducible transcriptions factors in the rat
hyppocampus: the effects of thyroid hormones and serotonin. J
Neurosci 2004, 20: 3926-35.
5. Andrews MH, Matthews SG. Programming of the hypothalamo-pi-
tuitary-adrenal axis: serotonergic involvment. Stress 2004, 7: 15-27.
6. Dinan TG. Serotonin and the regulation of hypothalamic-pituitary-
adrenal axis function. Life Sci 1996, 58: 1683-94.
7. Fuller RW, Snoddy HD. Serotonin receptor subtypes involved in the
elevation of serum corticosterone concentration in rats by direct-
and indirect-acting serotonin agonists. Neuroendocrinology 1990,
52: 206-11.
8. Heisler LK, Pronchuk N, Nonogaki K, et al. Serotonin activates the hy-
pothalamic-pituitary-adrenal axis via serotonin 2c receptor strimula-
tion. J Neurosci 2007, 27: 6956-64.
9. Bagdy G, Calogero AE, Aulakh CS, Szemeredi K, Murphy DL. Long-
term cortisol treatment impairs behavioral and neuroendocrine re-
sponses to 5-HT1 agonists in the rat. Neuroendocrinology 1989,
50: 241-7.
10. Di Sciullo A, Bluet-Pajot MT, Mounier F, Oliver C, Schmidt B, Kordon
C. Changes in anterior pitutitary hormone levels after serotonin 1A
receptor stimulation. Endocrinology 127: 567-72.













Neuroendocrine effect of citalopram in humans
662
11. Owens MJ, Knight DL, Ritchie JC, Nemeroff CB. The 5-hydrox-
ytryptamine2 agonist, (±)-1-(2,5-dimethoxy-4-bromophenyl)-2-amino-
propane stimulates the hypothalamic-pituitary-adrenal (HPA) axis. I.
Acute effects on HPA axis activity and corticotrophin-releasing fac-
tor-containing neurons in the rat brain. J Pharmacol Exp Ther 1991,
256: 787-94.
12. Power AC, Cowen PJ. Neuroendocrine challenge tests: assessment
of 5-HT function in anxiety and depression. Mol Aspects Med 1992,
1: 205-20.
13. Raap DK, Van de Kar LD. Selective serotonin reuptake inhibitors and
neuroendocrine function. Life Sci 1999, 65: 1217-35.
14. Lowe SL,Yeo KP, Teng L, et al. L-5-Hydroxytryptophan augments
the neuroendocrine response to a SSRI. Psychoneuroendocrinology
2006, 31: 473-84.
15. Arora RC, Gulati A, Crayton JW. Aging and 3H-paroxetine binding in
rat brain: effect of imipramine and tetrahydroacridine. Life Sci 1993,
52: 1767-75.
16. Yau JL, Kelly PA, Olsson T, Noble J, Seckl JR. Chronic amitriptyline
administration increases serotonin transporter binding sites in the
hyppocampus of aged rats. Neurosci Lett 1999, 261: 183-5.
17. Gross-Isseroff R, Salama D, Israeli M, Biegon A. Autoradiopgraphic
analysis of age-dependent changes in serotonin 5-HT2A receptors of
the human brain postmortem. Brain Res 1990, 19: 223-7.
18. Arranz B, Eriksson A, Mellerup E, Plenge P, Marcusson J. Effect of ag-
ing in human cortical pre- and postsynaptic serotonin binding sites.
Brain Res 1993, 620: 163-6.
19. Wong D, Wagner H, Dannals R, et al. Effects of age on dopamine
and serotonin receptors measured by positron emission tomogra-
phy in living human brain. Science 1984, 226: 226: 1393-6.
20. Tauscher J, Verhoeff NP, Christensen BK, et al. Serotonin 5-HT1A
receptor binding potential declines with age as measured by
[11C]WAY-100635 and PET. Neuropsychopharmacology 2001 24:
522-30.
21. Sheline YI, Mintun MA, Moerlein SM, Snyder AZ. Greater loss of 5-
HT(2A) receptors in midlife than in late life. Am J Psychiatry 2002,
159: 430-5.
22. Baeken C, D’Haenen H, Flamen P, et al. 123I-5-I-R91150, a new sin-
gle-photon emission tomography ligand for 5-HT2A receptors: influ-
ence of age and gender in healthy subjects. Eur J Nucl Med 1998,
525: 1617-22.
23. Møller M, Jakobsen S, Gjedde A. Parametric and regional maps
of free serotonin 5HT1A receptor sites in human brain as function
of age in healthy humans. Neuropsychopharmacology 2007, 32:
1707-14.
24. McBride PA, Tierney H, DeMeoM, Chen JS, Mann JJ. Effects of age
and gender on CNS serotonergic responsivity in normal adults. Biol
Psychiat 1990, 27: 1143-55.
25. Gelfin Y, Lerer B, Lesch KP, Gorfine M, Allolio B. Complex effects of
age and gender on hypothermic, adrenocorticotrophic hormone and
cortisol responses to ipsapirone challenge in normal subjects.
Psychopharmacology 1995, 120: 356-64.
26. Lerer B, Gillon D, Lichtenberg P, Gorfine M, Gelfin Y, Shapira B.
Interrelationship of age, depression, and central serotonergic func-
tion: evidence from fenfluramine challenge studies. Int Psychogeriat
1996, 8: 83-102.
27. O’Hara R, Schröder CM, Mahadevan R, et al. Serotonin transporter
polymorfism, memory, and hyppocampal volume in the elderly:
association and interaction with cortisol. Mol Psychiatry 2007, 12:
544-55.
28. Seifritz E, Baumann P, Müller MJ, et al. Neuroendocrine effects of a
20-mg citalopram infusion in healthy males. A placebo-controlled
evaluation of citalopram as 5-HT function probe. Neuropsy-
chopharmacology 1996, 14: 253-63.
29. Henning J, Netter P. Oral application of citalopram (20 mg) and its
usefulness for neuroendocrine challenge tests. Int J Neuropsy-
chopharmacol 2002, 5: 67-71.
30. Attenburrow MJ, Mitter PR, Whale R, Terao T, Cowen PJ. Low-dose
citalopram as a 5-HT neuroendocrine probe. Psychopharmacology
(Berl) 2001, 155: 323-6.
31. Flory JD, Manuck SB, Perel JM, Muldoon MF. A comparison of d, l-
fenfluramine and citalopram challenges in healthy adults.
Psychopharmacology (Berl) 2004, 174: 376-80.
32. Bhagwagar Z, Hafizi S, Cowen PJ. Acute citalopram administration
produces correlated increases in plasma and salivary cortisol.
Psychopharmacology (Berl) 2002, 163: 118-20.
33. Pariante CM, Papadopoulos AS, Poon L, et al. Four day of citalo-
pram increase suppression of cortisol secretion by prednisolone in
healthy volunteers. Psychopharmacology (Berl) 2004, 177 : 200-6.
34. Lotrich FE, Bies R, Muldoon MF, Manuck SB, Smith GS, Pollock BG.
Neuroendocrine response to intravenous citalopram in healthy con-
trol subjects: pharmacokinetic influences. Psychopharmacology (Berl)
2005, 178: 268-75.
35. Bhagwagar Z, Whale R, Cowen PJ. State and trait abnormalities in
serotonin function in major depression. Br J Psychiatry, 2002, 180:
24-8.
36. Kapitany T, Schindl M, Schindler SD, et al. The citalopram challenge
test in patients with major depression and in healthy controls.
Psychiatry Res 1999, 88: 75-88.
37. Pavlov EP, Harman SM, Chrousos GP, Loriaux DL, Blackman MR.
Responses of plasma adrenocorticotropin, cortisol, and dehy-
droepiandrosterone to ovine corticotropin-releasing hormone in
healthy aging men. J Clin Endocrinol Metab 1986, 62: 767-72.
38. Dodt C, Theine K, Uthgenannt D, Born J, Fehm HL. Basal secretory
activity of the hypothalamo-pituitary-adrenocortical axis is enhanced
in healthy elderly. An assessment during undisturbed night-time
sleep. Eur J Endocrinol 1994, 131: 443-50.
39. Van Cauter E, Leproult R, Kupfer DJ. Effetcs of gender and age on
the levels and circadian rhythmicity of plasma cortisol. J Clin
Endocrinol Metab 1996, 81: 2468-73.
40. Deuschle M, Gotthardt U, Schweiger U, et al. With aging in humans
the activity of the hypothalamus-pituitary-adrenal system increases
and its diurnal amplitude flattens. Life Sci 1997, 61: 2239-46.
41. Touitou Y, Sulon J, Bogdan A, et al. Adrenal circadian system in
young and elderly human subjects: a comparative study. J Endocrinol
1982, 93: 201-10.
42. Waltman C, Blackman MR, Chrousos GP, Riemann C, Harman SM.
Spontaneus and glucocorticoid-inhibited adrenocorticotropic hor-
mone and cortisol secretion are similar in healthy young and old
men. J Clin Endocrinol Metab 1991, 73: 495-502.
43. Dodt C, Dittmann J, Hruby J, et al. Different regulation of adreno-
corticotropin and cortisol secretion in young, mentally healthy el-
derly and patients with senile dementia of Alzheimer’s type. J Clin
Endocrinol Metab 1991, 72: 272-6.
44. Meijer OC, de Lange EC, Breimer DD, de Boer AG, Workel JO, de
Kloet ER. Penetration of dexamethasone into brain glucocorticoid
targets is enhanced in mdr1A P-glycoprotein knockout mice.
Endocrinology 1998, 139: 1789-93.
45. Sherman B, Wysham C, Pfohl B. Age-related changes in the circadi-
an rhythm of plasma cortisol in man. J Clin Endocrinol Meatb 1985,
61: 439-43.
46. Parker CR, Mixon RL Brissie RM, Grizzle WE. Aging alters zonation
in the adrenal cortex of men. J Clin Endocrinol Metab 1997, 82:
3898-901.
47. Mondelli V, Gianotti L, Picu A, et al. Neuroendocrine effects of citalo-
pram infusion in anorexia nervosa. Psychoneuroendocrinology 2006,
31: 1139-48.
48. Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal
hormone receptors in adrenal Cushing’s syndrome. Endocr Rev 2001,
22: 75-110.
49. Parker CR Jr, Azziz R, Potter HD, Boots LR. Adrenal androgen pro-
duction in response to adrenocorticotropin infusions in men. Endocr
Res 1996, 22: 717-22.
50. Arvat E, Di Vito L, Lanfranco F, et al. Stimulatory effect of adreno-
corticotropin on cortisol, aldosterone, and dehydroepiandrosterone
secretion in normal humans: dose-response study. J Clin Endocrinol
Metab 2000, 85: 3141-6.
51. Giordano R, Bo M, Pellegrino M, et al. Hypothalamus-pituitary-
adrenal hyperactivity in human aging is partially refractory to stimu-
lation by mineralocorticoid receptor blockade. J Clin Endocrinol
Metab 2005, 90: 5656-62.
52. Goodwin GM, Murray CL, Bancroft J. Oral D-fenfluramine and neu-
roendocrine challenge: problems with the 30 mg dose in men. J
Affect Disord 1994, 30: 117-22.
53. Ramasubbu R, Flint A, BrownG, AwadG, Kennedy S. Neurohormonal
responses to D-fenfluramine in healthy elderly subjects. A placebo-
controlled study. Psychoneuroendocrinology 2000, 25: 139-50.
JEI_10_010_Arvat.qxp:.  15-11-2010  15:23  Pagina 662
© 201
0, E
ditr
ic
Ku
tis
FOR
PER
SON
AL U
SE O
NLY
